UPDATE: JP Morgan Downgrades Luminex to Underweight

JP Morgan has downgraded Luminex LMNX from Neutral to Underweight and maintains its $18 price target in a research report published today. In the report, JP Morgan writies, "Given management 3Q commentary for more modest consumable growth in 2012, which was a significant source of top-line and margin growth in 1H11, we believe it is prudent to take a cautious stance on the stock, in light of difficult comps, premium valuation, and challenging end-markets. While we expect royalty and assay growth to remain strong for 2012, we believe that sustainable consumable growth (and/or much higher profitability for assays) will be necessary to support the current premium valuation, and are thus downgrading our rating to Underweight, while maintaining our December 2012 price target of $18." Shares of Luminex are trading at $20.09, down 1.90% from yesterday's close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsHealth CareJP MorganLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!